Table 1

Table 2

Table 3

Figures at a glance

Figure 1

Figure 2

Figure 3

Figure 4

Figure 5

Table 1

Age	Number	Percentage
˂ 35 years	1	1.63%
35 to 45 years	13	21.31%
46 to 55 years	16	26.22%
56 to 65 yars	15	24.59%
66 to 75 years	8	13.11%
˃ 75 years	5	8.19%
Not specified	3	4.91%

Table 1: Patient Age Distribution

Table 2

Sites	Number	Percentage
2/3 proximal vagina	16	26.22%
1/3 distal vagina	21	34.42%
Paramters	44	72.13%
Bladder	12	19.67%
Rectum	12	19.67%
Hydronephrosis	13	21.31%
Pelvic wall	1	1.64%
Adenomegalies	35	57.37%
Metastases	3	4.91%

Table 2:Tumour Extension Based on Sites Affected

Table 3

FIGO MRI Stage	Number	Percentage
Stage I	7	11.47%
Stage IIA	1	1.64%
Stage IIB	17	27.86%
Stage IIIA	2	3.27%
Stage IIIB	19	31.14%
Stage IVA	7	11.47%
Stage IVB	3	4.91%
No tumour	3	4.91%
Fibrosis	2	3.27%
Total	61	100%

Table 3: Distribution of Patients Based on FIGO MRI Stages

FIGURE 1

Figure 1: Hysterosalpingogram with metal cone instrument shows obliterated endometrial cavity except for most lower segment after contrast injection

FIGURE 2

Figure 2: Hysterosalpingogram with plastic catheter shows obliterated endometrial cavity except for most lower segment after contrast injection

FIGURE 3

Figure 3: Hystrosalpingogram scout film demonstrates multiple pelvic calcification indicating lymph nodes calcification

FIGURE 4

Figure 4: Hystrosalpingogram scout film demonstrates multiple pelvic calcification indicating lymph nodes calcification

FIGURE 5

Figure 5: Hystrosalpingogram scout film demonstrates multiple pelvic calcification indicating lymph nodes calcification